Over 130 million doses have already been administered worldwide. It's early days, but the signs are promising in places like Israel and the UK.
Academic rigour, journalistic flair
Articles on Oxford Vaccine
Displaying all articles
Vaccine developers pledge to create boosters that can better handle the new variants of the virus, and new data gives reassurance on the Oxford vaccine.
New trial data appears to support pushing back the second dose to 12 weeks.
It's going to be a huge logistical challenge.
Tensions run high as EU vaccine deliveries fall behind schedule, while new vaccines are being created to handle mutant viral strains.
The vaccine is still very likely to be protective in over-65s, even if efficacy in this age group is unknown.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
More than 2.5 billion doses have been ordered worldwide of the Oxford-AstraZeneca vaccine, providing a ray of hope in the fight against the pandemic.
Experts from across The Conversation assess the work that's helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
We need more data on the low-dose, high-dose regimen used in one arm of the trial, which may make the vaccine more effective.
Data coming through from phase 3 trials are encouraging. But participants don't represent the whole community — so we can't be sure these vaccines will work as well in everyone.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
What does this announcement mean for the world? It's potentially huge.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Michelle Grattan discusses the political week that was with Professor Paddy Nixon
Top contributors
-
Professor of Medicine, University of East Anglia
-
Senior Research Fellow in Global Health, University of Southampton
-
Professorial Fellow, University of Canberra
-
Professor in Global Public Health and Director of the Mitchell Institute, Victoria University
-
Associate professor, UNSW
-
Professor of Global Biosecurity, NHMRC Principal Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
Professor of Immunology and Associate Provost, Research Partnerships, Victoria University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Research Fellow, UNSW
-
Senior Research Fellow, South Western Sydney Clinical School, UNSW
-
Director, Centre for Big Data Research in Health, UNSW
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Senior Lecturer; MD, Victoria University
-
Senior Lecturer in Viral Immunology, University of Birmingham
